NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Red Queen Therapeutics

Red Queen Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://redqueentx.com/

Last Round

Grant

Aug 6, 2024

Total Funding Raised

$1.5M

Company Overview

Red Queen Therapeutics is a biotechnology company that develops antiviral therapeutics based on a proprietary stapled lipopeptide platform designed to block viral fusion and treat a broad range of viral infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

antiviral therapeuticsbroad-spectrum antiviralsstapled lipopeptidesdrug discoverybiotechviral resistancemedical countermeasurespan-influenza therapeuticfusion inhibitorsbiopharmaclinical-stage biotechBARDAdrug developmentinfectious disease treatmentpandemic preparedness

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Red Queen Therapeutics Comparables

Compare Red Queen Therapeutics with similar companies based on industry and business-model similarity.

Red Queen Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Thylacine Biotherapeutics
88%
Protinhi Therapeutics
83%
Cocrystal Pharma Inc
79%

Red Queen Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 6, 2024

Key People

Founding team and executive leadership

Mark Mitchnick

Chief Executive Officer

Executive Team

Red Queen Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors grew 96% MoM.

Red Queen Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Red Queen Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Red Queen Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range2
Year Founded2021
Last FundingAug 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.